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tissue necrosis, gross pulmonary embolism, and bacterial superinfection did not differentiate the 2 study
groups. Chest imaging at hospital admission did not differ either. CONCLUSIONS Extensive pulmonary
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Abstract
Background: Findings from autopsies have provided evi-
dence on systemic microvascular damage as one of the un-
derlying mechanisms of Coronavirus disease 2019 (CO-
VID-19). The aim of this study was to correlate autopsy-based 
cause of death in SARS-CoV-2, severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) positive patients with 
chest imaging and severity grade of pulmonary and systemic 
morphological vascular pathology. Methods: Fifteen SARS-
CoV-2 positive autopsies with clinically distinct presentations 
(age 22–89 years) were retrospectively analyzed with focus 
on vascular, thromboembolic, and ischemic changes in pul-
monary and in extrapulmonary sites. Eight patients died due 
to COVID-19 associated respiratory failure with diffuse alveo-
lar damage in various stages and/or multi-organ failure, 
whereas other reasons such as cardiac decompensation, 
complication of malignant tumors, or septic shock were the 
cause of death in 7 further patients. The severity of gross and 
histopathological changes was semi-quantitatively scored as 
0 (absent), 1 (mild), and 3 (severe). Severity scores between 
the 2 groups were correlated with selected clinical parame-
ters, initial chest imaging, autopsy-based cause of death, and 
compared using Pearson χ2 and Mann-Whitney U tests. Re-
sults: Severe pulmonary endotheliitis (p = 0.031, p = 0.029) 
and multi-organ involvement (p = 0.026, p = 0.006) correlated 
significantly with COVID-19 associated death. Pulmonary mi-
crothrombi showed limited statistical correlation, while tis-
sue necrosis, gross pulmonary embolism, and bacterial su-
perinfection did not differentiate the 2 study groups. Chest 
imaging at hospital admission did not differ either. Conclu-
sions: Extensive pulmonary endotheliitis and multi-organ in-
volvement are characteristic autopsy features in fatal CO-
VID-19 associated deaths. Thromboembolic and ischemic 
events and bacterial superinfections occur frequently in 
SARS-CoV-2 infection independently of outcome.
© 2021 The Author(s)
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Coronavirus disease 2019 (COVID-19) caused by the se-
vere acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) virus is a challenge for health-care systems and for 
affected patients worldwide [1]. Hypoxic respiratory failure 
is the leading cause of death in patients with severe CO-
VID-19 disease as is also seen in other respiratory viral in-
fections. The general histological correlate of acute respira-
tory distress syndrome (ARDS) is diffuse alveolar damage 
(DAD) characterized by intra-alveolar hyaline membrane 
formation, edema, and hemorrhage in the acute stage, fol-
lowed by fibroblast proliferation in the organizing stage. 
DAD is a nonspecific finding with a long list of potential 
etiologies, including other viral diseases, like influenza and 
SARS-CoV [2–4]. However, severe COVID-19 is associated 
with early pronounced gas exchange disturbance and par-
ticularly severe hypoxemic respiratory failure compared to 
the degree of radiographic abnormalities and more severe 
multi-organ failure compared to, for example, influenza, 
particularly in patients with vascular risk factors [2, 4–6].
Among the distinctive attributes of COVID-19 are as-
sociated microvascular changes and thrombosis [2, 7]. 
Endothelial cells not only play an important role in the 
pathogenesis of ARDS but also in the pathogenesis of 
multi-organ failure. This is thought to be due to vascular 
inflammation (endotheliitis) and mediating inflamma-
tory cell infiltration as well as apoptotic bodies found in 
different organ systems [7, 8]. This systemic endotheliitis 
with evidence of modulation of vessel barrier integrity, 
promoting a pro-coagulative state could thus explain the 
disproportional hypoxemia in relation to radiological 
changes and complications seen in different organs in pa-
tients with COVID-19 [9]. Quantitative RT-PCR results 
for SARS-CoV-2 also demonstrated that SARS-CoV-2 
has organotropism beyond the respiratory tract, includ-
ing the heart, the brain, skin, subcutaneous tissue, neuro-
muscular system, the kidneys, the intestine, and the liver 
[5, 6, 10–15]. Recent terms such as cardio-COVID-19 de-
fine the increased risk for cardiac injury, such as arrhyth-
mias, fulminant myocarditis, while neuromuscular-CO-
VID-19 refers to a broad spectrum of associated neuro-
muscular disorders, hyposmia, anosmia, etc [10–12].
Risk factors for a severe disease course of COVID-19, 
such as old age, obesity, hypertension, and diabetes mel-
litus are all risk factors for pre-existing vascular dysfunc-
tion with altered endothelial metabolism, and therefore 
might explain the worse outcome in these patient groups 
[16]. Since the outbreak of the pandemics, several further 
parameters including tissue-based factors have been 
identified in association with severe disease course in CO-
VID-19 [5, 6, 13, 17–19]. Complement activation and in-
creased neutrophilic infiltration of pulmonary capillaries 
and extracellular spaces (so called NETosis) have been 
described in autopsy studies and have been associated 
with an explosive inflammatory response and a poor 
prognosis in COVID-19 [17, 19, 20]. The interaction be-
tween viral-induced endothelial necrosis, excessive cyto-
kine production (“cytokine storm”), and a systemic viral 
vasculopathy syndrome have been described in several 
autopsy-based studies [5, 13, 18, 20]. A recent meta-anal-
ysis on published COVID-19 autopsies conclude that 
DAD is the most common pulmonary mortality cause 
and that a broad spectrum of ischemic necrosis, endothe-
liitis, and thromboembolism characterize extrapulmo-
nary COVID-19 disease [6]. Different from other respira-
tory pandemics, such as in SARS-CoV-1, the extensive 
thromboembolic events and multifocal endotheliitis is 
more often seen in COVID-19 [6]. Damaged endothelial 
cell activation and increased plasma von Willebrand fac-
tor antigen have been described as the key drivers in se-
vere COVID-19 disease along with associated coagulopa-
thy [21–23]. Whether a sum of the aforementioned fac-
tors or any single parameter alone may contribute to poor 
prognosis or can predict lethal outcome in COVID-19 is 
a challenging question to address in individual patients.
The aim of this study was to correlate autopsy-based 
cause of death in SARS-CoV-2 positive autopsies with se-
lected clinical parameters and with the severity grade of 
pulmonary and systemic morphological vascular patholo-
gy. We addressed the questions (a) whether SARS-CoV-2 
infection has any distinct morphological vascular pattern 
depending on the autopsy-based cause of death, (b) if pul-
monary thromboembolic events and bacterial superinfec-
tion have an impact on COVID-19-associated death, (c) 
how the involvement of extrapulmonary sites affects fatal 
outcome, and (d) if some clinical parameter may correlate 
with morphological findings or cause of death identified at 
autopsy. In order to answer these questions, we analyzed 15 
SARS-CoV-2 positive autopsies with 2 distinct clinical late 
phase disease patterns: 8 patients deceased due to CO-
VID-19 associated respiratory or multi-organ failure and 7 
patients died due to other reasons based on autopsy results.
Material and Methods
Postmortem examinations on 15 SARS-CoV-2 positive deceased 
patients were performed at the Institute of Pathology and Molecular 
Pathology of the University Hospital Zurich, Switzerland, according 
to standard procedures in a biosafety level 3 isolation room.




The diagnosis of SARS-CoV-2 infection was confirmed by real-
time reverse transcriptase-polymerase chain reaction testing (rRT-
PCR) on nasopharyngeal swabs prior to and during hospitalization 
in 14 of 15 patients. In 1 patient (patient 2), postmortem formalin-
fixed and paraffin-embedded (FFPE) lung tissue was positive for 
SARS-CoV-2 using rRT-PCR in the Reference Infectious Pathol-
ogy of Switzerland in the Institute of Pathology Cantonal Hospital 
Liestal Switzerland using the methodology as described earlier [5]. 
In all patients, a complete autopsy was performed including mac-
roscopic organ assessment and histological analysis of a predefined 
organ list. The organs of the central nervous systems were exam-
ined in the Institute of Neuropathology, University Hospital Zu-
rich (in collaboration with KF).
For histological diagnosis, tissue sections from FFPE tissues (2 
μm) from all organs (fixed in 4% paraformaldehyde) were stained 
with hematoxylin and eosin (H&E) according to standard tech-
niques. The diagnoses and histopathological features in this study 
were carried out on gross examination and using routine H&E 
stains on tissue sections. Fibrin thrombi were confirmed with fi-
brin stains (modified Picro-Mallory stain). A large subset of cases 
underwent further immunohistochemistry analyzes and were 
characterized by a panel of lympho- and hematopoietic and fur-
ther markers (such as CD3, CD4, CD45, CD68, and ACE2). Se-
lected lung, kidney, and heart samples were tested for the presence 
of viral particles and viral-like particles using FFPE or frozen snap 
tissues for immunofluorescence (in collaboration with XZ) and 
glutaraldehyde fixed samples for electron microscopy (in collabo-
ration with FS) as described earlier [5, 24, 25]. Postmortal swabs 
and FFPE samples of selected organs in a subset of autopsies were 
tested for SARS-CoV-2 by rRT-PCR as described above.
Patient Cohort
Altogether, 15 autopsies with SARS-CoV-2 infection were in-
cluded in this study. The first autopsy was performed in March 
Table 1. Clinical parameters in both groups with SARS-CoV-2 infection (patients 1–8 died from severe COVID-19, patients 9–15 died due 
other causes)
Clinical characteristics Patient
1° 2° 3° 4° 5+ 6+ 7+ 8+ 9 10 11 12 13 14 15
Age, years 70 77 58 79 56 61 79 72 22 69 67 87 58 89 78
Sex M F F M M M M M M F M F F M M
BMI, kg/m2 22.7 24.5 37 33.7 34.2 30.9 22.6 23.1 27.8 31.1 27.5 35 27.2 19.8 27.7
Days in hospital until death 8 9 18 7 19 20 18 40 1 32 11 5 23 2 28
Days intubated 8 0 17 0 15 1 0 20 1 0 10 4 15 0 24
Cardiovascular risk factors
Hypertension Yes Yes Yes Yes No No Yes Yes No Yes No Yes Yes Yes Yes
Diabetes No No Yes No No No No No No No No No Yes No No
Smoking (packs per year) Yes* 0 N/A Yes* 0 0 60 7.5 Yes* 0 N/A N/A 0 0 Yes*
Obesity1 No No Yes Yes Yes Yes No No No Yes No Yes No No No
Comorbidities
COPD No No No No No No Yes No No No Yes No No No No
Pulmonary hypertension No No No Yes No No No No No No No Yes No No No
Interstitial lung disease No No No Yes No No No No No No No No Yes No Yes
Asthma No No No No No No No No Yes No No No No No No
Coronary artery disease Yes No No No No No Yes No No No No No No Yes Yes
Hypertension cardiopathy No No Yes No No No Yes No No No No No No No No
Atrial fibrillation Yes No No Yes Yes Yes Yes Yes No No No Yes No No No
Chronic renal failure Yes No No Yes Yes No No Yes No Yes No No No Yes Yes
Malignant solid tumor (current) No No No No No No No No No Yes Yes No No Yes No
Malignant solid tumor (recurrence free) No Yes No No Yes No Yes No No No No No No No No
Solid organ transplantation Yes No No No Yes No No No No No No No No No No
Autoimmune disease No No No No No No No No No No No No Yes No No
Hematological disorder No No No Yes No Yes No No No No No No No No No
Depression No Yes No No No No No Yes No No No No Yes No No
Severity of disease
SOFA (mean) 12 N/A 12.3 N/A 11.5 10.5 N/A 10.9 17 N/A 12 11.5 7.4 N/A 8.75
SOFA (max) 14 N/A 19 N/A 16 15 N/A 18 17 N/A 12 12 11 N/A 11
SOFA (delta)2 2 N/A 11 N/A 7 9 N/A 12 0 N/A 5 1 −3 N/A 8
Patients 9–15 died due to other causes. N/A, not assessed; SOFA, Sequential Organ Failure Assessment; SARS-CoV-2, severe acute re-
spiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; BMI, body mass index. 1 Obesity was defined as BMI >30. 2 Differ-
ence of SOFA score upon admission and last registered score. ° Patient of the first COVID-19 wave – death due to COVID-19. + Patient of 





2020 and the autopsy of the last included subject was performed in 
January 2021. Ten patients were male and 5 patients were female. 
Age at the time of the autopsy ranged between 22 and 89 years 
(median 72.9 years). All 15 patients were hospitalized (2–40 days, 
median 16.6 days). Five patients were not mechanically ventilated 
(do not intubate order) and 10 patients were intubated (intubation 
time ranged between 1 and 24 days [median 11.5 days]). Cardio-
vascular risk factors were present in all 15 patients: hypertension 
in 10 of 15 patients (67%), diabetes mellitus in 2 of 15 patients 
(13%), and smoking in 6 of 15 patients (40%), in 3 of 15 patients, 
there was no information on smoking from patient history. Obe-
sity defined as body mass index >30 kg/m2 was present in 6 of 15 
patients (40%). Comorbidities included COPD (2 of 15), pulmo-
nary hypertension (2 of 15), chronic interstitial lung disease (3 of 
15), asthma (1 of 15), coronary artery disease (4 of 15), hyperten-
sive heart disease (2 of 15), atrial fibrillation (7 of 15), chronic renal 
failure (7 of 15), current malignant tumor (3 of 15), recurrence-
free malignant tumor (3 of 15), solid organ transplantation (2 of 
15), autoimmune disorder (1 of 15), hematological disease (2 of 
15), and depression (3 of 15). Clinical data are shown Table 1.
Statistical Analyses
Statistical analysis was performed using IBM SPSS Statistics for 
Windows, Version 26.0. IBM Corp., Armonk, NY, USA. The Mann-
Whitney U test and Pearson R test were used for comparison of mor-
phological findings in autopsy tissue between groups. p value <0.05 
was regarded as statistically significant. Parameters being statistically 
significant with both tests were weighted as biologically relevant. 
Graphics were plotted using GraphPadPrism (version 9.0).
Scoring of Autopsy Findings and Definition of Groups
Definition of Severity Scores
Macro- and histopathological scoring: Various parameters 
were scored according to the severity of histological appearance 
and/or gross findings. Score 0: absent (not apparent on H&E sec-
tion and/or not evident with ancillary immunohistochemistry). 
Low intensity as score 1 (discrete and modest changes were pooled 
in 1 low intensity score 1): discrete (score 1) and modest (score 2) 
presence of macro -und histopathological feature only in small an-
atomical compartments and in focal (only 1 anatomical region) or 
only in scattered (in max. 2 anatomical compartments per organ) 
distribution. Ancillary tests were used if not apparent on H&E 
staining. Score 3: diffuse expression of the feature involving mul-
tiple (>2 foci per organ) anatomical compartments.
Multi-organ involvement and necrosis scoring: 1 score point 
was allocated to each organ showing histological signs of endothe-
liitis or necrosis, respectively. The sum of all affected organs was 
taken as the final score.
Definition of Biological Groups
To test the hypothesis “correlation of morphological autopsy 
findings with clinical course/severity/cause of death in SARS-
Cov-2 positive deceased patients”, autopsy cases were assigned to 
1 of 2 groups. Group 1: “Death due to COVID-19” were patients 
with fatal course of COVID-19 disease – hospitalized due to CO-
VID-19 and autopsy-based cause of death was due to respiratory 
or cardio-respiratory failure with diffuse alveolar damage. Group 
2: “Death due to other causes” were SARS-CoV-2 positive patients, 
with or without clinical symptoms of COVID-19 and death de-
fined at autopsy due to other causes such as underlying disease, for 




Macroscopic examination of the lungs was in line with 
full ARDS in 8 cases (Nr 1–8, 100% of the group) and 
showed a broad panel of gross lesions in 7 further cases. 
Patient Cause of death Death due to 
COVID-19
1° Respiratory failure with diffuse alveolar damage Yes
2° Respiratory failure with diffuse alveolar damage Yes
3° Respiratory failure with diffuse alveolar damage Yes
4° Respiratory failure with diffuse alveolar damage Yes
5 Respiratory failure with diffuse alveolar damage Yes
6 Respiratory failure with diffuse alveolar damage Yes
7 Respiratory failure with diffuse alveolar damage Yes
8 Respiratory failure with diffuse alveolar damage Yes
9 Acute myocardial infarction No
10 Complication, metastatic colorectal cancer No
11 Complication, metastatic non-small cell lung cancer No
12 Cardiac decompensation and pulmonary hypertension No
13 Cardio-respiratory insufficiency due to chronic interstitial lung disease No
14 Complication, metastatic malignant melanoma No
15 Septic shock and pulmonary aspergillosis No
COVID-19, coronavirus disease 2019.   Patients of first COVID-19 wave.
Table 2. Cause of death based on overall 
findings at autopsy




There were bilateral diffuse or focal, partially confluent 
large pale to yellowish hemorrhagic zones of consolida-
tion and edema (shown in Fig. 1d, h). Macroscopic pul-
monary infarction was evident in 6 of 15 cases (40%), 
macroscopic thromboembolism in 5 of 15 cases (30%).
Histological Findings
Microscopic examination of the lungs revealed signs 
of DAD in different stages in 8 patients (53%) who died 
from COVID-19. Bronchopneumonia was identified in 8 
of 15 cases (53%). Endotheliitis of small and medium-
sized pulmonary vessels was seen in all but 1 patient (14 
of 15, 93%) (Fig. 1a, e). Fibrin thrombi were evident in 7 
of 15 cases (47%) (Fig. 1b, f) and leucocytic vessel occlu-
sion (“leucocytic thrombi”) in 9 of 15 cases (60%) (Fig. 1c, 
g). Thrombotic vessel occlusions were noted within a few 
small pulmonary artery branches as often seen in DAD 
but also in small to medium-sized vessels and in areas not 
affected by DAD.
The extension of pulmonary endotheliitis significantly 
correlated with autopsy-based cause of death due to CO-
VID-19 (R-test p = 0.031, U test p = 0.029) (Fig. 2a, 3a). 
Individual severity scores of macro and microscopic pa-
thology findings are shown in Table 3.
Viral RNA was evident in 30–80% of selected organs 
in 10 of 15 autopsies, being the highest in lung samples 
and showing a lower but similar distribution in the extra-
pulmonary organs (see online suppl. Fig. 1; see www.
karger.com/doi/10.1159/000518914 for all online suppl. 
material). There was no statistically significant difference 
in RNA positive samples between the 2 study groups (χ2 
test, p = 0.991, not significant at p < 0.05).
Chest CT Morphology
Chest computed tomography (CT) at initial hospital 
admission showed a different extent of bilateral pulmo-
nary ground-glass opacities and consolidations in both 
autopsy groups. Severe or mild vascular damage at au-
topsy did not correlate with the extent of pulmonary 
ground-glass opacities, which was evidenced in patients 
who died due to COVID-19 and those who succumbed to 
other underlying causes (Fig. 4a–d).
Vascular Postmortem Findings in Further Organ 
Involvement
Heart
Endotheliitis was a frequent finding in the small in-
tramyocardial and subepicardial vessels present in all 
3 cm
5 cm
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e f g h
Fig. 1. Histological vascular and gross pulmonary vascular find-
ings in SARS-CoV-2 positive autopsies. Images demonstrate se-
vere grade of vascular changes (larger involved areas and high 
number of foci) (a–d), images show mild grade morphological 
changes (smaller or only scattered areas involved) (e–h). Numer-
ous (a) and only scattered (e) lymphocytes beneath the endothe-
lium. Multiple middle- and small-sized (b and c) and only scat-
tered small-sized peripheral (f, g) fibrin and leucocytic thrombi. 
Large multiple areas (d) and only small foci (h) of pulmonary hem-
orrhagic infarction and consolidation. a–g: H & E stain. b (inset): 
modified Picro-Mallory stain. H&E, hematoxylin and eosin; 





but 2 cases (13/15). Fibrin thrombi were less frequent 
(5 of 15 cases, 30%) and leucocytic thrombi in 7 of 15 
cases (47%).
Kidney
Acute tubular necrosis was a frequent finding seen in 
13 of 15 patients (87%). In contrast to the lungs and the 
heart, the kidneys demonstrated only very mild endothe-
liitis with few infiltrating cells in 2 of 15 patients (13%).
Liver
Patchy centrilobular hepatocyte necrosis and conflu-
ent necrosis associated with fibrin thrombi in the respec-
tive vessels were found in those patients with multi-organ 
failure (in 8 of 15 cases [53%]).
Small Intestine
Small intestine necrosis was present in 4 of 15 patients 
(27%), leading in the setting of multi-organ failure to death 
in all 4 patients. Identical histomorphological changes were 
seen in all cases, with microangiopathic chances of the sub-
mucosal vessels consisting of fibrin thrombi, endotheliitis, 
and apoptotic endothelial cells. Individual severity scores of 
pathology findings are shown in Table 3.
Association between cause of death based on autopsy 
findings and vascular manifestations of COVID-19
Severe pulmonary endotheliitis (R-test p = 0.031, U 
test p = 0.029) and multi-organ involvement of CO-
VID-19 (R-test p = 0.026, U test p = 0.006) correlated sig-
nificantly with COVID-19 associated death (Fig. 2, 3; Ta-
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Fig. 3. a The extension of pulmonary endo-
theliitis (R-test p = 0.031, U test p = 0.029) 
and b) the evidence of multi-organ in-
volvement (R-test p = 0.026, U test p = 
0.006) correlated significantly with CO-
VID-19 associated cause of death (Pearson 










































Fig. 2. Correlation between severity scores 
of macroscopic and histopathological find-
ings and autopsy-based cause of death in 
SARS-CoV-2 positive autopsies. Axe Y 
demonstrates mean score per gross or his-
topathological pulmonary findings (a) and 
of organ involvement (b). Axe X shows the 
distribution of autopsy findings in terms of 
cause of death identified at the autopsy. The 
extension of pulmonary endotheliitis and 
the evidence of multi-organ involvement 
correlated significantly with COVID-19 as-
sociated cause of death. Individual scores 
are shown in Table 3. Statistical correlation 
between scores and autopsy-based cause of 
death is shown in Table 4. SARS-CoV-2, se-
vere acute respiratory syndrome coronavi-
rus 2; COVID-19, coronavirus disease 
2019; CT, computed tomography.




Fig. 4. Chest CT morphology in SARS-CoV-2 infected and de-
ceased patients at initial hospital admission. CT images show no 
correlation to different extent of histopathological and gross vas-
cular changes at the autopsy and are not associated with clinical 
course. Images (a, c) show diffuse bilateral pulmonary consolida-
tions (with severe and mild histopathological changes, respective-
ly). Image (b) displays focal consolidations at severe histopatho-
logical findings at autopsy. Image (d) shows diffuse bilateral pul-
monary consolidations at only mild histopathological changes at 
autopsy. SARS-CoV-2, severe acute respiratory syndrome corona-
virus 2; COVID-19, coronavirus disease 2019; CT, computed to-
mography.
Table 3. Scores of histological and gross macroscopic findings at autopsy
Histological scoring Patients
1° 2° 3° 4° 5+ 6+ 7+ 8+ 9 10 11 12 13 14 15
Lung1
Endotheliitis2 3 3 3 1 3 1 3 1 0 1 1 1 1 1 1
Fibrin thrombi2 1 1 1 1 3 0 1 0 0 0 1 0 0 0 0
Leucocytic thrombi2 3 1 1 0 3 0 1 0 0 0 3 1 1 1 0
Infarction 1 0 0 0 3 3 3 3 0 0 0 0 0 1 0
Bronchopneumonia2 0 0 0 0 1 0 1 3 3 0 3 0 1 3 3
Macroscopic thrombi 0 0 0 0 1 3 3 3 1 0 0 0 0 0 0
Heart1
Endotheliitis2 1 1 1 1 3 0 3 1 1 1 1 0 1 1 0
Fibrin thrombi2 1 0 1 1 3 0 3 0 0 0 0 0 0 0 0
Leucocytic thrombi2 0 0 3 0 3 0 3 0 0 0 1 1 1 1 0
All organ systems
Involved organs 5 2 4 3 2 3 3 4 2 2 2 1 2 2 1
Endotheliitis in different organs2, 3 9 2 8 5 6 3 9 3 2 2 2 1 2 2 1
Necrosis in different organs 3 0 2 1 3 1 4 0 1 1 2 2 2 2 1
Patients 9–15 died due to other causes. COVID-19, coronavirus disease 2019. 1 Pooled low intensity score 1 ver-
sus high intensity score 3. 2 Microscopic evaluation only. 3 Sum score of all affected organs. ° Patients of the first 






































































more frequent in COVID-19 associated death (U test p = 
0.040), while tissue necrosis, gross thromboemboli, and 
bacterial superinfection did not differentiate the 2 study 
groups. Chest imaging at hospital admission did not dif-
fer either and lacked correlation to any pathological fac-
tors analyzed. We did not find any statistically relevant 
interaction between clinical SOFA scores, the use of ven-
tilation and morphological parameters at the autopsy.
Discussion
In this study, we retrospectively analyzed the correla-
tion between morphological vascular findings, autopsy-
based cause of death and clinical parameters (such as SOFA 
score) and chest imaging in 15 COVID-19 autopsies with 
a different clinical course. We could show in our cohort 
that severe grade pulmonary endotheliitis, multi-organ in-
volvement of endotheliitis, and tissue necrosis significant-
ly correlate with COVID-19 associated death. Vascular 
changes were less prevalent in COVID-19 positive patients 
dying from other causes. Pulmonary infarction, broncho-
pneumonia, grossly visible pulmonary embolism, and fre-
quent neutrophilic thrombi were common pathological 
findings in the autopsies. However, disease severity and 
cause of death did not correlate with these additional find-
ings. Neither the initial chest CT imaging nor clinical dis-
ease severity parameters such as SOFA score or duration 
of ventilation correlated with autopsy findings or morpho-
logical cause of death. According to our knowledge, this 
autopsy-based study is the first to address the relationship 
between the magnitude and site involvement of morpho-
logical vascular changes, clinical parameters, and autopsy-
based cause of death in COVID-19 autopsies.
The correlation between morphological pathological 
autopsy findings and imaging modalities especially chest 
CT at initial presentation or hospitalization have been the 
subject of several previous studies [8, 22, 26–29]. In a pre-
vious autopsy-based study, the typical ground-glass opac-
ities on imaging harbored a high correlation to a broad 
spectrum of pulmonary autopsy findings; however, all 
these patients died due to COVID-19 so a correlation to 
the cause of death in SARS-CoV-2 positive autopsies was 
not possible [27]. In our autopsy series, 7 SARS-CoV-2 
positive patients died due to other causes than COVID-19 
although a direct comparison between initial CT images 
and the magnitude of histopathological and gross autop-
sy findings or RNA viral evidence in selected organs did 
not show any association. These findings were seen in all 
patients, independent of the use of mechanical ventila-
tion in our cohort, and are similar to those described in 
COVID-19 autopsy series from other centers as well as in 
influenza pneumonia and findings during the 2002–2003 
SARS (SARS-CoV-1) pandemic [4, 27, 30–32].
Table 4. Summary of statistical comparison between cause of death (2 groups) and autopsy findings as well as SOFA score in SARS-CoV-2 
positive autopsies
Clinical course of disease
SOFA (mean) SOFA (max) SOFA (delta)
Pearson χ2 0.540 0.189 0.358














Pearson χ2 0.031 0.060 0.875 0.084 0.186 0.182










Pearson χ2 0.026 0.113 0.138 0.374
Mann-Whitney 0.006 0.001 0.955 1.000
p values <0.05 are considered as statistically significant. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SOFA, Sequen-
tial Organ Failure Assessment.




The correlation between clinical parameters (such as 
SOFA scores or neutrophilic activation) to disease course 
has been observed in previous studies indicating the pos-
sibility to monitor disease severity [17, 19]. In our series, 
the relationship between dynamic SOFA scores and the 
degree of histopathological and gross vascular autopsy 
findings did not prove to be significant and we could not 
identify any morphological factors in our autopsy series 
harboring a link to clinical SOFA scores. Interestingly, 
none of the SOFA scores (mean, maximal, and delta) 
could be correlated to COVID-19 associated cause of 
death in our series, possibly pointing to the biological role 
and relevance of global immunological SARS-CoV-2 in-
duced host response independently of morphological dis-
ease extension. However, the extent of endotheliitis has 
been described to be associated with critical illness and 
fatal COVID-19 disease, which further strengthens our 
data [21].
The extent of endothelial damage described in this 
study is most prominent in the lung, while extrapulmo-
nary manifestations are less evident. Endothelial cell in-
jury at the blood-gas barrier may explain the observed 
high alveolo-arterial gradient with pronounced hypox-
emia both in spontaneous breathing patients with less se-
vere dyspnea than expected and in the early phase of me-
chanical ventilation with severe hypoxemia but initially 
only mildly reduced lung compliance than ARDS of oth-
er origins [1, 8, 17, 19, 22, 23, 33, 34]. Corroborating with 
these clinical, tissue, and autopsy-based previous obser-
vations, our study data support the preferential role of the 
magnitude in pathological vascular alterations especially 
in pulmonary vascular involvement and the role of mor-
phological multi-organ involvement in COVID-19 [17, 
19, 21, 22].
The vascular pattern described in this study may explain 
the adverse outcome of COVID-19 in patients with pre-
existing endothelial dysfunction, and thus less capacity to 
restore the injured vasculature and inhibit microthrombo-
sis. In line with the observed association of the extent of 
systemic microvascular damage with clinical signs of organ 
failure in this study, circulating markers of endotheliopa-
thy were associated with mortality in a plasma profiling 
study in a small sample of COVID-19 patients.
Endothelial tropism and endothelial cell apoptosis 
have been observed in case of infection with other respi-
ratory viruses, for example, influenza A infection or 
SARS-CoV-1 have been suggested as underlying mecha-
nism of, for example, encephalopathy in influenza infec-
tion [35, 36]. In an autopsy-based meta-analysis, SARS-
CoV-1, Influenza A, and SARS-CoV-2 infections share 
the high prevalence of DAD as the main pulmonary pa-
thology; however, extrapulmonary findings are different 
especially in terms of multifocal pulmonary and extrapul-
monary thrombosis and multifocal endotheliitis pointing 
to higher frequency of multi-organ involvement at CO-
VID-19 [2, 5, 6]. It is however at current time not possible 
to answer the question whether the multi-organ involve-
ment triggers the endotheliitis or contrariwise or whether 
both factors represent 2 biologically distinct mechanisms 
in COVID-19. If the endothelium of the blood-gas bar-
rier is damaged or dysfunctional, both diffusion impair-
ment and ventilation-perfusion mismatch will further in-
crease and aggravate hypoxemia [8, 23, 26, 28]. Therefore, 
treatment strategies that reduce ventilation-perfusion 
mismatch might be particularly important (e.g., prone 
positioning). The effect of substances active on the pul-
monary endothelium needs to be systematically studied. 
Secondary preventive measures in patients with pre-ex-
isting endothelial dysfunction who seem to be prone to a 
severe course of COVID-19 might be of epidemiological 
interest [17, 19, 22, 33]. Therapeutic implications of the 
described vascular damage, such as anticoagulation are 
established, however, which other interventions might be 
helpful against the procoagulant state in case of microvas-
cular damage are still subject to debate [17, 19, 22]. 
Whether survivors of severe COVID-19 will suffer from 
long-term vascular damage (e.g., pulmonary hyperten-
sion or COVID-19-promoted atherosclerosis) and other 
consequences of microvascular damage-associated multi-
organ failure should be systematically studied during a 
long-term follow-up.
Limitations of the Study
The small sample size (n = 15 autopsies) and the vari-
able clinical presentations (such as diverging time-frame 
between first diagnosis and death, different postmortem 
time to autopsy and individual pre- and in-hospital treat-
ment) likely explain why morphological vascular find-
ings and viral RNA evidence in available selected tissues 
are discordant in this study. Discrepant results between 
virus detection and clinical outcome have been described 
in previous studies and were linked to numerous co-fac-
tors such as the presence of viral load in vivo, the disease 
phase and treatment modalities [5, 13, 18, 37]. Higher 
viral load resulting from direct viral attack is consequent-
ly mostly measured in pulmonary vessels, while extrapul-
monary sites (e.g., kidney, skin, brain, heart, etc.) harbor 
rather a low viral load due to docking pseudovirions 







In conclusion, our autopsy-based data show that a dis-
tinct histopathological pattern in terms of extensive pul-
monary endotheliitis and manifestation of systemic 
multi-organ vascular and tissue damage correlates with 
COVID-19 associated death and differs in SARS-CoV-2 
positive patients dying due to other causes. Pulmonary 
infarction, bronchopneumonia, grossly visible pulmo-
nary embolism and increased neutrophilic thrombi were 
common pathological findings in autopsies of SARS-
CoV-2 positive patients independent of disease severity 
or the cause of death. Clinical parameters such as initial 
chest CT imaging, SOFA score, duration of ventilation, or 
tissue-based viral RNA evidence did not correlate with 
autopsy findings or with morphological cause of death. 
The vascular pattern in fatal COVID-19 described here is 
another piece of the puzzle to support treatment strate-
gies focusing on the endothelium, inflammatory re-
sponse, and on avoidance of thrombi.
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